4DMT to Present at ARVO 2024 Annual Meeting

4D Molecular Therapeutics (4DMT), a clinical-stage company at the forefront of genetic medicines, is set to make significant presentations at the 2024 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting in Seattle, Washington, from May 5-9, 2024. The company will share advancements in their innovative genetic therapies aimed at treating critical eye conditions.

One highlighted presentation will discuss interim findings from the PRISM Phase 2 Dose Expansion trial, which evaluates 4D-150 in individuals with neovascular (wet) age-related macular degeneration who have a high need for anti-VEGF treatments. This session is scheduled for May 8, 2024, at 10:30 a.m. PT. The results will be presented by Dr. Arshad M. Khanani, a noted figure in clinical research and a Clinical Associate Professor at the University of Nevada, Reno School of Medicine.

Another key presentation will focus on preclinical data for 4D-175, an investigational intravitreal gene therapy for geographic atrophy, a significant cause of vision loss. This oral presentation will be delivered by Dr. Melissa A. Calton, VP of Early-Stage Product Development at 4DMT, on May 9, 2024, at 12:00 p.m. PT.

These presentations underscore 4DMT's commitment to advancing genetic medicines for ophthalmologic conditions. The company leverages its proprietary Therapeutic Vector Evolution platform, a cutting-edge technology that harnesses directed evolution and synthetic AAV capsid-derived sequences to develop tailored vectors. This platform aims to create customized solutions for specific diseases, enhancing the efficacy and safety of genetic therapies.

4DMT’s pipeline includes five clinical-stage and two preclinical product candidates addressing ophthalmology, pulmonology, and cardiology. Additionally, the company is exploring gene editing solutions for central nervous system (CNS) diseases through strategic partnerships.

The company's product candidates are still under clinical and preclinical investigation and have not yet received marketing approval from the FDA or any other regulatory bodies. Therefore, no claims regarding their safety or effectiveness can be made at this stage.

4DMT continues to innovate in the field of genetic medicine, aspiring to develop therapies that could potentially transform the treatment landscape for numerous patients. The presentations at the ARVO Annual Meeting reflect the company's ongoing efforts and progress in this specialized medical sector.